Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of DAR BIOSCIENCE, INC. ("DAR " OR THE "COMPANY"). THIS PRES

Delivering innovation by daring to be

different September 5, 2018 Exhibit 99.1

Forward Looking Statements This

presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of DAR BIOSCIENCE, INC. ("DAR " OR THE "COMPANY"). THIS PRESENTATION INCLUDES CERTAIN

INFORMATION OBTAINED FROM TRADE AND STATISTICAL SERVICES, THIRD PARTY PUBLICATIONS, AND OTHER SOURCES. DAR HAS NOT INDEPENDENTLY VERIFIED SUCH INFORMATION AND THERE CAN BE NO ASSURANCE AS TO ITS ACCURACY. ALL STATEMENTS IN This

presentation, OTHER THAN STATEMENTS OF HISTORICAL FACT, ARE forward-looking statements within the meaning of federal securities laws. IN SOME CASES, YOU CAN IDENTIFY FORWARD-LOOKING STATEMENTS BY TERMS SUCH AS "MAY," "WILL,"

"EXPECT," "PLAN," "ANTICIPATE," "Strategy," "designed," "COULD," "INTEND," "BELIEVE," "ESTIMATE," "Target," OR

"POTENTIAL" AND OTHER SIMILAR EXPRESSIONS, OR THE NEGATIVE OF THESE TERMS. Forward-looking statements involve risks, uncertainties and assumptions that may cause DAR 'S actual results, performance or achievements to be

materially different from THOSE expressed or implied by the forward-looking statements, INCLUDING, WITHOUT LIMITATION risks and uncertainties relating to: the outcome or success of clinical trials; DAR 's ability to raise additional

capital as needed; DAR 's ability TO OBTAIN AND MAINTAIN INTELLECTUAL PROPERTY PROTECTION FOR ITS PRODUCT CANDIDATES; DAR 'S ABILITY TO DEVELOP product candidates ON THE TIMELINEs set forth HEREIN; and other risk factors

described in DAR 's most recent annual report on form 10-K and quarterly report on form 10-q filed with the Securities and Exchange Commission. All forward-looking statements in this presentation are current only as of the date hereof and

DAR does not undertake any obligation to update any forward-looking statement to reflect new information, future developments or otherwise, except as required by law.

Vision: To become the coordinating

presence in women's health. Mission: We achieve this by identifying, unlocking and advancing innovation that improves health outcomes and promotes a better quality of life for women. Vision & Mission

Dar Highlights Daring to be

different A pure play biopharmaceutical company focused on improving the health and well being of women. Focused on targeted delivery of products to address persistent unmet needs in women's health: Pregnancy Prevention Sexual Health Vaginal

Health Fertility The portfolio is well positioned to drive upside value in the short and long term and each asset is positioned to be a first-in-category opportunity. Multiple milestones and value drivers expected over the next 12 - 24 months:

Advancing our two Phase 2 programs, and Initiating development activities on Phase 1 and preclinical programs.

Coordinating Innovation in

Women's Health Dar is building a strong and strategic network to advance innovation in women's health. Global Women's Health Market Worth $51 Billion by 2025 - CAGR: 3.9% 1 1.

https://www.prnewswire.com/news-releases/womens-health-market-size-worth-513-billion-by-2025--cagr-39-grand-view-research-inc-651064753.html Women's Health Network of Product Developers Women's Health Network of Potential Commercial

Partners* Strategic Science & Technologies *Company names and logos are for illustrative purposes only.

Portfolio Overview Timeline reflects

management's current estimates and constitutes a forward looking statement subject to qualifications elsewhere in the presentation. Actual development timeline may be substantially longer, and Dar is under no obligation to update or

review this estimate. CDRH / Device Lead Innovative Women's Health Pipeline ^505(b)(2). *Ovaprene Post Coital Test (PCT) is a pre-pivotal clinical study.. HRT Phase 1 study to be conducted in Australia by Dar subsidiary.

Ovaprene (PCT)* Topline 2H 2019 Pregnancy Prevention (Contraception) Topical 5% Sildenafil Citrate Cream Topline 4Q 2020 Female Sexual Arousal Disorder DARE-HRT1^ Topline 2H 2019 Hormone Replacement Therapy Formerly JNP-0201 DARE-FRT1^

Preterm Birth / Infertility (IVF) Formerly JNP-0301 DARE-OAB1^ Overactive Bladder Formerly JNP-0101 DARE-VVA1^ Vulvar Vaginal Atrophy Formerly PT-101 DARE-RH1 Contraception Formerly CatSper ORB 204 & 214^ Contraception Topical Cream sildenafil

IVR estradiol + progesterone Vaginal Insert SERM IVR natural progesterone IVR oxybutynin Injectable sustained release etonogestrel Barrier IVR ferrous gluconate Ca2+ Target

1. Global Market Insights,

https://globenewswire.com/news-release/2016/05/19/841462/0/en/Contraceptives-Market-size-to-exceed-33-Billion-by-2023-Global-Market-Insights-Inc.html Contraception $32 billion global category1

Innovation in Contraception Advances in

hormone products have largely focused on reducing the hormone dosage, adjusting or extending the duration of protection and optimizing methods of administration. Convenience is driving new innovation NuvaRing Monthly, convenient vaginal ring

product form. 2017 revenue: $761 million (Merck).5 Mirena Physician inserted, long-acting. Low/locally delivered hormone IUS. 2017 revenue: $1.12 billion (Bayer).5 What's Driving Innovation in Contraception 1. Lo

Loestrin Fe contains a low-dose combination of two female hormones. https://www.loloestrin.com/loloestrin/about-lo-loestrin. Lo Loestrin and its design are registered trademarks of Allergan Pharmaceuticals

International Limited. 2. Minastrin https://www.minastrin24.com. Minastrin is a registered trademark of Allergan Pharmaceuticals International Limited. 3. https://www.nuvaring.com/how-nuvaring-works/ 4. https://www.mirena-us.com/about-mirena/

5. 2017 SEC Financial Filings 1 2 3 4

The US Contraceptive Market is Large

>$6 billion in US Rx sales of contraceptive products (2016).1 40 million women of reproductive age currently use a contraceptive method.2 Ready for Innovation 4 in 10 women not satisfied with their current method.2 ~50% of women opting for a

shorter-acting reversible method.3 Limited product mix in the OTC non-hormonal contraceptive category Most non-hormonal options are over the counter (OTC) and are not optimal in terms of effectiveness or convenience. Largest SKUs in the OTC channel

are condoms and Plan-B.4 U.S. Contraceptive Market $6 Billion IMS NSP through Dec 2016 www.guttmacher.org, contraceptive fact sheet Ersek, J, Matern Child Health J (2011) 15:497-506 IRI Data

Women's Preferences Effective

Pregnancy Prevention Convenient Product Forms Independent surveys revealed that the vaginal ring has many of the features women deemed extremely important.1 Less Hormones A majority of women prefer a monthly option with a lower hormone dose than the

pill.2 Methods not in the moment (noncoital) 75% of women who practice contraception currently use non-coital (not in the moment) methods.3 What Women Want from Birth Control Lessard, L,Perspectives on Sexual and Reproductive Health, Volume 44,

Number 3,9-2012 Hooper, DJ, Clin Drug Investig. 2010;30(11):749 63 https://www.guttmacher.org/fact-sheet/contraceptive-use-united-states

Non-hormonal Products (marketed or

in development) Spermicides / vaginal gels Least effective woman controlled. On-demand / pre-coital application. Condoms Effective, not woman controlled. On-demand / pre-coital application. Diaphragms Most effective woman controlled. On-demand /

pre-coital insertion. Long-acting IUD Most effective. Requires physician insertion/removal. What's Driving Innovation in Contraception Innovation in Contraception - What's Missing? Non-hormonal, non-coital alternatives that are effective

and easy to use. 100% Effective = 0% Risk of Pregnancy / vaginal gels Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY:

Ardent Media, 2011. http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf 1 1,2 A non-hormonal, non-daily, woman controlled option with efficacy approaching traditional hormonal methods aligns well with consumer need

Ovaprene A New Contraceptive

Opportunity Monthly Non-Hormonal Opportunity

Ovaprene Non-hormonal, Monthly

Vaginal Ring Spermiostatic Environment1 Achieved through a contraceptive-loaded silicone ring matrix. Releasing non-hormonal active Ferrous gluconate. Physical Barrier1 3-D, non-braided, fluid-permeable mesh barrier. Rx distribution (OB/GYN) -

anticipated upon approval. Patent Protection1 12 issued patents worldwide (9 U.S.). IP coverage through August 2028. Potential extension to 2033. 1. Data on file Ovaprene A New Contraceptive Opportunity

2009 - Postcoital Assessment:1

Open-label, single-arm, pilot safety and tolerability study. Published in the Journal of Reproductive Medicine, 2009. Patients: N= 21; all women completed one cycle of use. Results: Postcoital testing revealed no viable sperm in the cervical mucus.

No colposcopic abnormalities, no significant changes in vaginal flora and no serious adverse effects observed. Ovaprene Non-hormonal, Monthly Vaginal Ring Ovaprene successfully prevented sperm from reaching the cervical canal in a previous

human postcoital test (PCT) clinical study. In PCT studies of similar size, products (diaphragms) with no motile sperm in the cervical mucus during their PCT assessments demonstrated "typical use" contraceptive effectiveness of 88% in

pivotal contraceptive studies evaluating pregnancy rates over time. Journal of Reproductive Medicine 2009; 54: 685-690 Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive

Technology: Twentieth Revised Edition. New York, NY: Ardent Media, 2011. http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/CTFailureTable.pdf 2,3 Ovaprene A New Contraceptive Opportunity

Step 1 - Postcoital test (PCT)

2018 / 2019* The study is enrolling 50 couples. 25 women complete a total of 21 visits Evaluated over the course of five menstrual cycles. Each woman's cervical mucus will be examined at several points during the study: Cycle 1 - Baseline

(excludes the use of any product), Cycle 2 - Use of a barrier method (diaphragm), Cycles 3,4 and 5 - Ovaprene vaginal ring. Assess motile sperm per high powered field (HPF) in the cervical mucus, post coitus. Safety assessments, PK,

acceptability, fit, and ease of use. *Anticipated regulatory pathway and timelines. Dare has not had any communications with the FDA regarding the specific PMA requirements for Ovaprene. Ovaprene Non-hormonal, Monthly Vaginal Ring U.S.

Regulatory Strategy PMA with CDRH (Medical Device Division) as lead review division. Pathway expected to be based on similar CDRH approvals - Example: Caya diaphragm.* Step 2 - Pivotal Study 2020 / 2021* Single pivotal clinical

(expected). N= ~250 completers over 6 months of use. Primary Endpoints: Safety & Efficacy Pregnancy probability. Secondary Endpoints: Acceptability /product fit/ ease of use. Assessments of vaginal health. Ovaprene A New Contraceptive

Opportunity Data from the study is expected to be available in the second half of 2019. If there is demonstration of feasibility in the PCT clinical trial, the Company intends to prepare and file an Investigational Device Exemption (IDE) with the

FDA to commence a pivotal clinical trial to support marketing approvals of Ovaprene in the United States, Europe and other countries worldwide.

https://www.urban.org/urban-wire/women-want-effective-birth-control Lessard, L,Perspectives on Sexual and Reproductive Health, Volume 44, Number 3,9-2012 Hooper, DJ, Clin Drug Investig. 2010;30(11):749 63 Ersek, J, Matern Child Health J (2011)

15:497-506 Journal of Reproductive Medicine 2009; 54: 685-690 Features Desired Most in Birth Control:1-4 Design Features of Ovaprene:5 Convenience (Easy to Use & Easy to Remember) Monthly Ring Product Form Women chose rings for the

convenience of a non-daily option. Hormone Free No Hormones in the API Unique dual action MOA (spermiostatic & barrier). Efficacy Potential for Contraceptive Effectiveness at the Lower End of the Hormone Contraceptive Range. Favorable Side

Effect Profile No Colposcopic Abnormalities No significant changes in vaginal flora. No serious adverse effects observed in prior published study. Easily Manage Fertility No Systemic Activity Inserted and removed without a provider. Immediate return

to fertility. Ovaprene A New Contraceptive Opportunity Ovaprene Non-hormonal, Monthly Vaginal Ring

https://www.visiongain.com/Press_Release/911/Sexual-dysfunction-drugs-market-will-reach-7-7bn-in-2019 Female Sexual Arousal Disorder (FSAD) World market for both male and female sexual dysfunction drugs will reach 7.7 billion in 20191 Women's

Sexual Health & Wellness

Vulvar-Vaginal Atrophy Female Sexual

Arousal Disorder (FSAD) Dyspareunia Hypoactive Sexual Desire Disorder (HSDD) Female Sexual Dysfunction (FSD) With its approval of Addyi , FDA has now acknowledged and formally classified the distinct and separate disorders that comprise Female

Sexual Dysfunction. Where HSDD is characterized primarily by a lack of sexual desire, FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal. Female Sexual Dysfunction Market Landscape No Approved

Products INTRAROSA is a registered trademark of Endoceutics, Inc. Imvexxy is a trademark of TherapeuticsMD, Inc. Osphena is a registered trademark of Duchesnay USA, Pennsylvania, USA. ESTRACE is a registered trademark of Allergan

Pharmaceuticals International Limited. Premarin is a registered trademark of Pfizer Inc. Addyi is a registered trademark of Sprout Pharmaceuticals, Inc. Bremelanotide is a registered trademark of Palatin Technologies, Inc.

Female Sexual Arousal Disorder

(FSAD) FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal; it is also characterized by distress or interpersonal difficulty.* Estimated 23-33% of women suffer from arousal disorder: Meta-analysis

of 95 studies from 2000-2014 indicated the prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 40.9%, and difficulty with arousal alone is 23%.1 33% of women in the U.S. age 21 to 60 (approximately 20 million women),

experience symptoms of low or no sexual arousal.2,3 10 million women are considered distressed and actively seeking treatment.2 Female Sexual Arousal Disorder FSAD McCool et al. Sex Med Rev 2016;4:197-212. Ad Hoc Market Research: FSAD Prevalence

Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. *Diagnostic and Statistical Manual 4th Edition Text Revision (DSM IV TR), defines female sexual arousal disorder as a persistent or recurrent inability to attain or to

maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement. The diagnostic criteria also state that the inability causes marked distress or interpersonal difficulty, is not better accounted for

by another Axis I disorder (except another sexual dysfunction), and is not due exclusively to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition.

Female Sexual Arousal Disorder

(FSAD) Dar licensed the rights to Topical 5% Sildenafil Citrate Cream in February, 2018 for all women's health indications related to female sexual dysfunction and female reproductive health. In a Phase 2a study, Topical 5% Sildenafil

Citrate Cream formulation demonstrated an increase in blood flow to the vaginal tissue in both pre- and postmenopausal women with FSAD. Topical 5% Sildenafil Citrate Cream FSAD

Twelve healthy premenopausal

women were studied. P<0.05 P=0.093 P=0.015 P=0.017 Question #2 - "After taking study medication, the sensation/feeling in my genital (vaginal, labia, clitoris) area during intercourse or stimulation (foreplay) seemed to be:

(a) more than before, (b) less than before, or (c) unchanged". Question #4 - "After taking the study medication, intercourse and/or foreplay was: (a) pleasant and satisfying; better than before taking the study medication, (b)

unpleasant; worse than before taking study medication, (c) unchanged; no difference, or (d) pleasant; but still not like it used to be or I would like it to be." 202 postmenopausal women with FSAD who had protocol specified estradiol and free

testosterone concentrations, and/or were receiving estrogen and/or androgen replacement therapy were studied. Pfizer VPA Clinical Lab Study - Oral Viagra Pfizer Clinical Field Study - Oral Viagra Pfizer Viagra Studies

Increased Blood Flow and Clinical Efficacy with Oral Sildenafil in Women Female Sexual Arousal Disorder (FSAD) Sildenafil Demonstrated Statistically Significant Results Statistically significant increases in Vaginal Pulse Amplitude (VPA)1

Statistically significant improvement in genital stimulation (FIEI)2 Female Intervention Efficacy Index (FIEI) The Enhancement of Vaginal Vasocongestion by Sildenafil in Healthy Premenopausal Women. Journal of Women's Health & Gender-Based

Medicine. Vol. 11, No. 4. 2002 Safety and Efficacy of Sildenafil Citrate for the Treatment of FSAD: A Double-Blind, Placebo Controlled Study. The Journal of Urology. Vol 170, 2333-2338, December 2003.

Female Sexual Arousal Disorder

(FSAD) Topical 5% Sildenafil Citrate Cream - Formulation Innovation Topical 5% Sildenafil Citrate Cream designed to directly increase local blood flow to the genital tissue. Localized action, with minimal systemic uptake of the active drug.1 6